BIOFIRE® FILMARRAY® Pneumonia (PN) Panels
1 Test. 33 Targets. ~1 Hour.
Quickly and accurately pinpoint the probable pathogen with this multiplex molecular panel, which tests for 33 of the most common pathogens associated with lower respiratory tract infections.
Pneumonia Testing Redefined
Pneumonia patients are frequently over-treated with antibiotics because it is difficult to quickly identify the pathogen responsible for their symptoms. The BIOFIRE PN Panel is a response to this challenge. The single test comprehensively identifies 33 potential pathogen targets from sputum-like (including endotracheal aspirate) and bronchoalveolar lavage (BAL)-like (including mini-BAL) samples. For 15 of the bacteria, the BIOFIRE PN Panel provides semi-quantitative results, which may help determine whether an organism is a colonizer or a pathogen.
The Power Behind the Panel
The BIOFIRE PN Panel can provide the essential combination of speed, accuracy, and comprehensiveness to enable a rapid, definitive identification of a pathogen.
How the BIOFIRE PN Panel Helps
The BIOFIRE PN Panel transforms diagnostics by swiftly delivering results within about one hour, a significant improvement over conventional methods. Its enhanced pathogen detection capability may improve diagnostic accuracy, while also contributing to more informed antimicrobial prescribing. This innovative approach further aids in patient care by facilitating quicker and more targeted treatment decisions.
The Pneumonia Testing Menu
Discover the 33 targets on the BIOFIRE PN Panel, including eight viruses, 18 bacteria, and seven antimicrobial resistance genes associated with lower respiratory tract infections.
Sample Type
BAL-like: (including mini-BAL)
Sputum: (including endotracheal aspirate)
Performance
BAL-like: 96% sensistivity and 98.3% specificity
Sputum: 96.3% sensitivity and 97.2% specificity
Syndromic Testing Made Simple
The BIOFIRE® FILMARRAY® Systems run syndromic infectious disease tests. One multiplex assay simultaneously tests for the most common pathogens and antimicrobial resistance genes associated with a particular syndrome.
The BIOFIRE® FILMARRAY® TORCH System
The BIOFIRE TORCH System uses multiplex PCR technology to simultaneously test for a comprehensive grouping of targets in about an hour.
- Compatible with six-panel syndromic portfolio
- Reduced footprint provides up to six times the throughput per square foot of laboratory bench space
- Scalable configuration allows customized throughput
- Simplified workflow features a touchscreen interface and integrated barcode scanner
- Data management automation includes LIS connectivity and random-access operation
The BIOFIRE® FILMARRAY® 2.0 System
The BIOFIRE 2.0 System enables simplified test ordering, faster turnaround times, and increased accuracy by minimizing manual data entry.
- Scalable configuration allows customized throughput and efficient use of laboratory bench space
- Offers LIS connectivity, random-access operation, and single database management of up to 8 instruments per computer
Service & Support
To order the BIOFIRE PN Panel, contact your regional sales representative or use the following contact information:
Email: salesorders@biofiredx.com
Phone: 1-801-736-6354
US Sales Extension: 1502
International Sales Extension: 1536
Product Information
| PRODUCT NAME | PART NUMBER | QUANTITY |
|---|---|---|
| BIOFIRE Pneumonia 30 Pouch Kit | RFIT-ASY-0144 | 30-Pack |
1. Data on File at BioFire Diagnostics.
2. El-Nawawy A.A. et al. Comparison of a Point-of-Care FilmArray Test to Standardof-Care Microbioloty Test in Diagnosis of Healthcare Associated Infections in a Tertiary Care Pediatric Intensive Care Unit Antibiotics 2022, 11, 453. doi:10.3390/ antibiotics11040453.
3. Jain S, Self WH, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.The New England journal of medicine. 2015;373(5):415-427. doi:10.1056/NEJMoa1500245.
4. Data on file, bioMérieux. The stated performance is the overall aggregate performance of the prospective clinical study data presented in the IFU. Performace data is for pathogen detection only.
5. Poole S., et al. Molecular point-of-care testing for lower respiratory tract pathogens improves safe antibiotic de-escalation in patients with pneumonia in the ICU: results of a randomised controlled trial. Journal of Infection 2022. Dec;85(6):625-633. doi:10.1016/j.jinf.2022.09.003.
